T1D5
MCID: TYP031
MIFTS: 48

Type 1 Diabetes Mellitus 5 (T1D5)

Categories: Endocrine diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Type 1 Diabetes Mellitus 5

MalaCards integrated aliases for Type 1 Diabetes Mellitus 5:

Name: Type 1 Diabetes Mellitus 5 57 11 28 5 14
Latent Autoimmune Diabetes in Adults 11 43 14 16 75
Diabetes Mellitus, Insulin-Dependent, 5 57 73 12 71
Iddm5 57 11 73
Insulin-Dependent Diabetes Mellitus 5 57 11
Diabetes Mellitus, Insulin-Dependent, Type 5 38
Type 1.5 Diabetes 11
T1d5 57
Lada 11

Classifications:



External Ids:

Disease Ontology 11 DOID:0080846 DOID:0110744
OMIM® 57 600320
ICD10 31 E10
MedGen 40 C1838260
UMLS 71 C1838260

Summaries for Type 1 Diabetes Mellitus 5

UniProtKB/Swiss-Prot: 73 A form of diabetes mellitus, a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

MalaCards based summary: Type 1 Diabetes Mellitus 5, also known as latent autoimmune diabetes in adults, is related to hypothyroidism and hashimoto thyroiditis. An important gene associated with Type 1 Diabetes Mellitus 5 is SUMO4 (Small Ubiquitin Like Modifier 4), and among its related pathways/superpathways are NF-kappaB Signaling and CD28 co-stimulation. The drugs Metformin and Zinc cation have been mentioned in the context of this disorder. Affiliated tissues include lymph node, pancreatic islet and thyroid, and related phenotypes are Increased apoptosis and homeostasis/metabolism

Disease Ontology 11 Type 1 diabetes mellitus 5: A type 1 diabetes mellitus that has material basis in mutation of the SUMO4 gene on chromosome 6q25.1.

Latent autoimmune diabetes in adults: A type 1 diabetes mellitus that is characterized by a less intensive autoimmune process, highly variable β-cell destruction, different degrees of insulin resistance and heterogeneous titre and pattern of islet autoantibody, sharing features with both type 1 and type 2 diabetes mellitus.

Wikipedia: 75 Slowly evolving immune-mediated diabetes, or latent autoimmune diabetes in adults (LADA), is a form of... more...

More information from OMIM: 600320

Related Diseases for Type 1 Diabetes Mellitus 5

Diseases in the Diabetes Mellitus family:

Type 1 Diabetes Mellitus 2 Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus 3
Type 1 Diabetes Mellitus 4 Type 1 Diabetes Mellitus 5
Type 1 Diabetes Mellitus 7 Type 1 Diabetes Mellitus 8
Type 1 Diabetes Mellitus 11 Type 1 Diabetes Mellitus 13
Type 1 Diabetes Mellitus 12 Type 2 Diabetes Mellitus 2
Type 1 Diabetes Mellitus 15 Type 1 Diabetes Mellitus 6
Type 1 Diabetes Mellitus 10 Type 1 Diabetes Mellitus 17
Type 2 Diabetes Mellitus 3 Diabetes Mellitus, Congenital Autoimmune
Type 1 Diabetes Mellitus 18 Type 2 Diabetes Mellitus 4
Type 1 Diabetes Mellitus 19 Type 1 Diabetes Mellitus 20
Type 1 Diabetes Mellitus 21 Type 1 Diabetes Mellitus 22
Type 1 Diabetes Mellitus 23 Type 1 Diabetes Mellitus 24
Type 2 Diabetes 5 Rare Diabetes Mellitus Type 1
Rare Diabetes Mellitus Type 2 Rare Diabetes Mellitus

Diseases related to Type 1 Diabetes Mellitus 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 hypothyroidism 30.6 TG PTPN22 INS HLA-DQB1 CTLA4
2 hashimoto thyroiditis 30.5 TNFRSF25 TG PTPN22 GAD2 CTLA4
3 type 1 diabetes mellitus 3 30.5 SLC30A8 SLC30A10 INS
4 autoimmune polyendocrine syndrome 30.4 TG PTPN22 GAD2
5 vitiligo-associated multiple autoimmune disease susceptibility 1 30.3 TG PTPN22 CTLA4
6 diabetes mellitus, ketosis-prone 30.3 SLC30A8 SLC30A10 PTPRN INSM2 INS GAD2
7 insulinoma 30.3 SLC30A8 PTPRN2 PTPRN INSM2 INS CPE
8 thyroiditis 30.3 TNFRSF25 TG PTPN22 INS HLA-DQB1 HLA-DQA1
9 hirata disease 30.2 TNFRSF10A SLC30A8 SLC30A10 INS HLA-DQA1
10 juvenile rheumatoid arthritis 30.1 PTPN22 HLA-DQB1 HLA-DQA1
11 graves disease 1 30.0 TG INS
12 maturity-onset diabetes of the young 30.0 SLC30A8 SLC30A10 PTPRN INSM2 INS GAD2
13 autoimmune hepatitis 29.9 PTPN22 HLA-DQB1 CTLA4
14 pernicious anemia 29.8 TOR1A TNFRSF25 TG PTPRN PTPN22 INS
15 autoimmune disease 29.3 TG PTPRN PTPN22 INS HLA-DQB1 HLA-DQA1
16 type 1 diabetes mellitus 28.9 TNFRSF25 TG SUMO4 SLC30A10 PTPRN2 PTPRN
17 celiac disease 1 28.5 TOR1A TNFRSF25 TNFRSF10A TG SLC30A8 SLC30A10
18 diabetes mellitus 28.2 TNFRSF25 TG SUMO4 SLC30A8 SH2B3 PTPRN2
19 oto-palatal-digital syndrome 10.7
20 type 2 diabetes mellitus 10.7
21 abdominal obesity-metabolic syndrome 1 10.4
22 49, xxxxy syndrome 10.4
23 down syndrome 10.3
24 microvascular complications of diabetes 5 10.3
25 neuropathy 10.3
26 primary agammaglobulinemia 10.3
27 ulcer of lower limbs 10.3 TNFRSF10A INS
28 juvenile dermatitis herpetiformis 10.3 TNFRSF25 HLA-DQA1
29 adult-onset myasthenia gravis 10.3 HLA-DQA1 CTLA4
30 pemphigoid gestationis 10.3 TNFRSF25 TNFRSF10A
31 amelogenesis imperfecta, type ib 10.3 TNFRSF25 TNFRSF10A
32 podoconiosis 10.2 HLA-DQB1 HLA-DQA1
33 isthmus cancer 10.2 TG PTPRN
34 bleeding disorder, platelet-type, 17 10.2 PTPRN2 INSM2
35 chondromalacia 10.2 TNFRSF10A HLA-DQA1
36 alcohol dependence 10.2
37 erythermalgia, primary 10.2
38 oculodentodigital dysplasia 10.2
39 hypothyroidism, congenital, nongoitrous, 2 10.2
40 microvascular complications of diabetes 1 10.2
41 hypothyroidism, congenital, nongoitrous, 3 10.2
42 microvascular complications of diabetes 2 10.2
43 microvascular complications of diabetes 3 10.2
44 microvascular complications of diabetes 4 10.2
45 microvascular complications of diabetes 6 10.2
46 microvascular complications of diabetes 7 10.2
47 monocarboxylate transporter 1 deficiency 10.2
48 non-alcoholic fatty liver disease 10.2
49 rickets 10.2
50 prediabetes syndrome 10.2

Graphical network of the top 20 diseases related to Type 1 Diabetes Mellitus 5:



Diseases related to Type 1 Diabetes Mellitus 5

Symptoms & Phenotypes for Type 1 Diabetes Mellitus 5

Clinical features from OMIM®:

600320 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Type 1 Diabetes Mellitus 5 according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 CPE CTLA4 GAD2 HLA-DQA1 HLA-DQB1 INS
2 no effect GR00402-S-2 10.18 CPE CTLA4 GAD2 HLA-DQA1 INS INSM2
3 Increased apoptosis GR00093-A-0 9.13 PTPN22 PTPRN PTPRN2

MGI Mouse Phenotypes related to Type 1 Diabetes Mellitus 5:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 CPE CTLA4 GAD2 HLA-DQB1 INS PTPN22
2 endocrine/exocrine gland MP:0005379 10 CPE CTLA4 GAD2 HLA-DQA1 HLA-DQB1 INS
3 immune system MP:0005387 9.8 CPE CTLA4 GAD2 HLA-DQA1 HLA-DQB1 INS
4 hematopoietic system MP:0005397 9.44 CPE CTLA4 HLA-DQA1 HLA-DQB1 INS PTPN22

Drugs & Therapeutics for Type 1 Diabetes Mellitus 5

Drugs for Type 1 Diabetes Mellitus 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
2
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
3
Saxagliptin Approved Phase 4 361442-04-8 11243969
4
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
5
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
6 Vitamins Phase 4
7 Insulin, Globin Zinc Phase 4
8
Insulin Phase 4
9 Trace Elements Phase 4
10 Calciferol Phase 4
11 Micronutrients Phase 4
12 Hypoglycemic Agents Phase 4
13 Hormones Phase 4
14 Hormone Antagonists Phase 4
15 Calcium, Dietary Phase 4
16 HIV Protease Inhibitors Phase 4
17 Dipeptidyl-Peptidase IV Inhibitors Phase 4
18 Incretins Phase 4
19
protease inhibitors Phase 4
20
Calcium Nutraceutical Phase 4 7440-70-2 271
21
Aluminum sulfate Approved Phase 2 10043-01-3
22
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
23
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
24 Anti-Ulcer Agents Phase 2
25 Adjuvants, Immunologic Phase 2
26 Antacids Phase 2
27 Gastrointestinal Agents Phase 2
28 Immunologic Factors Phase 2
29
Sitagliptin Phosphate Phase 1, Phase 2 654671-77-9
30
Insulin aspart Approved 116094-23-6 16132418
31
Rosiglitazone Approved, Investigational 122320-73-4, 155141-29-0 77999
32
Glyburide Approved 10238-21-8 3488
33
Repaglinide Approved, Investigational 135062-02-1 65981
34 Insulin aspart, insulin aspart protamine drug combination 30:70
35 Protamines
36 Autoantibodies
37 Insulin, Isophane
38 Isophane Insulin, Human
39 Isophane insulin, beef

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled, Open-label, Multi-center Study With 104-week Saxagliptin or (and) Vitamin D3 Assessing Protective Effects on Beta Cell Function in Latent Autoimmune Diabetes in Adults (LADA) Treated With Metformin (and Insulin) Completed NCT02407899 Phase 4 Saxagliptin;Vitamin D3;Insulin;Metformin
2 Early Insulin Treatment in Patients With Latent Autoimmune Diabetes (LADA) Completed NCT01109927 Phase 4 Insulin
3 Effects of Berberine Plus Inulin on Diabetes Care in Patients With Latent Autoimmune Diabetes in Adults: A Randomized Controlled Trial Not yet recruiting NCT04698330 Phase 4 Berberine;Inulin;Berberine placebo tablets;Inulin placebo tablets
4 A Pilot Study on Safety, Feasibility and Insulin-promotion by Intra-inguinal Lymph Node Injections of Glutamic Acid Decarboxylase (GAD) in Patients With LADA Type of Diabetes Completed NCT04262479 Phase 2 recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel;Vitamin D
5 A Placebo-Controlled Study to Investigate the Impact of Diamyd® on the Diabetes Status of Patients With LADA (Latent Autoimmune Diabetes in Adult) Completed NCT00456027 Phase 2 rhGAD65 formulated in Alhydrogel® (Diamyd®)
6 Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA) Completed NCT01159847 Phase 1, Phase 2 sitagliptin;Insulin
7 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Tolerability as Well as the Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in LADA Subjects Terminated NCT00058981 Phase 2 DiaPep277
8 Randomized, Controlled, Parallel-Group Prospective Study to Investigate the Clinical Effectiveness of Early Insulin Treatment in Patients With Latent Autoimmune Diabetes in Adults Unknown status NCT00776607 NovoMix 30;Tablet treatment
9 Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes Completed NCT00194896 rosiglitazone;glyburide
10 A Study of the Genetic Causes of Latent Autoimmune Diabetes in Adults Completed NCT01793974
11 Detection of Latent Autoimmune Diabetes in Adults, Clinical and Metabolic Profile in Patients Treated at the Diabetes Clinic in a Hospital in the Mexican Southeast. Completed NCT05235672
12 Is "Beta Cell Rest" by Insulin Treatment Beneficial Compared to State-of-the Art Enhancers of Insulin Secretion in Preserving Beta Cell Function in Subjects With Latent Autoimmune Diabetes of the Adult (LADA)? Completed NCT01140438 metformin+ NPH insulin;metformin + sitagliptin +/- repaglinide
13 Autoimmune Diabetes: Disease Markers and Treatment of Latent Autoimmune Diabetes in Adults (LADA) Withdrawn NCT01148238

Search NIH Clinical Center for Type 1 Diabetes Mellitus 5

Cochrane evidence based reviews: latent autoimmune diabetes in adults

Genetic Tests for Type 1 Diabetes Mellitus 5

Genetic tests related to Type 1 Diabetes Mellitus 5:

# Genetic test Affiliating Genes
1 Type 1 Diabetes Mellitus 5 28 SUMO4

Anatomical Context for Type 1 Diabetes Mellitus 5

Organs/tissues related to Type 1 Diabetes Mellitus 5:

MalaCards : Lymph Node, Pancreatic Islet, Thyroid, T Cells, Pancreas, Neutrophil, Ovary

Publications for Type 1 Diabetes Mellitus 5

Articles related to Type 1 Diabetes Mellitus 5:

(show top 50) (show all 863)
# Title Authors PMID Year
1
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. 62 57 5
15247916 2004
2
A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. 57 5
15123604 2004
3
Confirmation of three susceptibility genes to insulin-dependent diabetes mellitus: IDDM4, IDDM5 and IDDM8. 62 57
8733139 1996
4
A genome-wide search for human type 1 diabetes susceptibility genes. 62 57
8072542 1994
5
Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. 5
15678135 2005
6
Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. 5
15678134 2005
7
Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. 5
15678137 2005
8
Two genetic loci regulate T cell-dependent islet inflammation and drive autoimmune diabetes pathogenesis. 57
10848492 2000
9
A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. 57
9662408 1998
10
Smoking, use of smokeless tobacco, HLA genotypes and incidence of latent autoimmune diabetes in adults. 62
35900371 2023
11
Can SARS-CoV-2 trigger new onset of autoimmune disease in adults? A case-based review. 62
36338884 2022
12
The continuous spectrum of glycaemic variability changes with pancreatic islet function: A multicentre cross-sectional study in China. 62
36214297 2022
13
Altered brain spontaneous and synchronization activity in latent autoimmune diabetes in adults: A resting-state functional MRI study. 62
36306532 2022
14
Diagnostic camouflage: A case report on Latent autoimmune diabetics of adulthood. 62
36268330 2022
15
Genome-resolved analyses show an extensive diversification in key aerobic hydrocarbon-degrading enzymes across bacteria and archaea. 62
36203131 2022
16
Linking the region-specific tissue microstructure to the biaxial mechanical properties of the porcine left anterior descending artery. 62
35905825 2022
17
Birthweight, BMI in adulthood and latent autoimmune diabetes in adults: a Mendelian randomisation study. 62
35606578 2022
18
Adult-onset autoimmune diabetes. 62
36138034 2022
19
Efficacy and safety of sitagliptin and insulin for latent autoimmune diabetes in adults: A systematic review and meta-analysis. 62
35445591 2022
20
Sphingomyelin profiling in patients with diabetes could be potentially useful as differential diagnostics biomarker: A pilot study. 62
35785598 2022
21
Thyroid autoantibody distribution in patients with latent autoimmune diabetes in youth: a multicenter, national survey. 62
36111021 2022
22
Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adults in a patient with hashitoxicosis as first presentation of Hashimoto's thyroiditis: a case report. 62
35918735 2022
23
Multifocal Neuroarthropathy of the Knee and Foot Induced by Physical Training of the Lower Extremities in a Patient With Latent Autoimmune Diabetes in Adults. 62
36148208 2022
24
Latent autoimmune diabetes in youth shows greater autoimmunity than latent autoimmune diabetes in adults: Evidence from a nationwide, multicenter, cross-sectional study. 62
35451144 2022
25
The Association of CTLA-4 rs231775 and rs3087243 Polymorphisms with Latent Autoimmune Diabetes in Adults: A Meta-Analysis. 62
34822071 2022
26
Locality Adaptive Discriminant Analysis Framework. 62
33502996 2022
27
Locality-Aware Crowd Counting. 62
33534703 2022
28
Rapid Point-of-Care Test for Determination of C-Peptide Levels. 62
33729032 2022
29
Prevalence and factors associated with latent autoimmune diabetes in adults (LADA): a cross-sectional study. 62
35804315 2022
30
Nursing a patient with latent autoimmune diabetes in adults with insulin-related lipodystrophy, allergy, and exogenous insulin autoimmune syndrome: A case report. 62
36051121 2022
31
Atypical Diabetes and Management Considerations. 62
35595479 2022
32
The role of renal damage markers in the diagnosis of early stages of kidney injury in patients with latent autoimmune diabetes in adults. 62
35928354 2022
33
Small RNAs are differentially expressed in autoimmune and non-autoimmune diabetes and controls. 62
35616612 2022
34
Early life Bacillus Calmette-Guerin vaccination and incidence of type 1, type 2, and latent autoimmune diabetes in adulthood. 62
35245655 2022
35
Self-reported Severe and Nonsevere Hypoglycemia in Type 1 Diabetes: Population Surveillance Through the BETTER Patient Engagement Registry: Development and Baseline Characteristics. 62
35835670 2022
36
Mutual enhancing learning-based automatic segmentation of CT cardiac substructure. 62
35447610 2022
37
An Unsuspected Case of Euglycemic Diabetic Ketoacidosis With Twists. 62
35573514 2022
38
Prediction of Heat Transfer and Fluid Flow Effects on Entropy Generation in a Monolithic Catalytic Converter Using Large-Eddy Simulation. 62
35626487 2022
39
Diagnostic Dilemmas and Current Treatment Approaches in Latent Onset Autoimmune Diabetes in Adults: A Concise Review. 62
35331118 2022
40
Erratum. Characteristics of the Gut Microbiota and Metabolism in Patients With Latent Autoimmune Diabetes in Adults: A Case-Control Study. Diabetes Care 2021;44:2738-2746. 62
35020835 2022
41
Time-dependent effects on circulating cytokines in patients with LADA: A decrease in IL1-ra and IL-1 beta is associated with progressive disease. 62
35066451 2022
42
The Differential Expression of Circular RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults. 62
35349376 2022
43
Two Fifth-Generation Fighter Pilots Discovered with Latent Autoimmune Diabetes. 62
35105428 2022
44
Progression of Diabetic Complications in Subgroups of People with Long Term Diabetes Type 1 According to Clinical Course. 62
32777840 2022
45
A Case of Late Diagnosis of Latent Autoimmune Diabetes in Adults. 62
35282513 2022
46
Assessment of Hydrocarbon Degradation Potential in Microbial Communities in Arctic Sea Ice. 62
35208784 2022
47
Identification of long-chain alkane-degrading (LadA) monooxygenases in Aspergillus flavus via in silico analysis. 62
36110294 2022
48
Lifestyle or Environmental Influences and Their Interaction With Genetic Susceptibility on the Risk of LADA. 62
35846274 2022
49
Serum Bile Acid Profiles in Latent Autoimmune Diabetes in Adults and Type 2 Diabetes Patients. 62
35242878 2022
50
GAD65 Antibody Epitopes and Genetic Background in Latent Autoimmune Diabetes in Youth (LADY). 62
35392100 2022

Variations for Type 1 Diabetes Mellitus 5

ClinVar genetic disease variations for Type 1 Diabetes Mellitus 5:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TAB2, SUMO4 NM_001002255.2(SUMO4):c.163G>A (p.Val55Met) SNV Pathogenic
2062 rs237025 GRCh37: 6:149721690-149721690
GRCh38: 6:149400554-149400554

Expression for Type 1 Diabetes Mellitus 5

Search GEO for disease gene expression data for Type 1 Diabetes Mellitus 5.

Pathways for Type 1 Diabetes Mellitus 5

GO Terms for Type 1 Diabetes Mellitus 5

Cellular components related to Type 1 Diabetes Mellitus 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi apparatus GO:0005794 10.07 TNFRSF10A SLC30A8 SLC30A10 PTPRN HLA-DQA1 GAD2
2 cytoplasmic vesicle GO:0031410 9.7 TOR1A SLC30A8 PTPRN2 PTPRN GAD2 CPE
3 secretory granule GO:0030141 9.56 TOR1A SLC30A8 PTPRN2 PTPRN
4 transport vesicle membrane GO:0030658 9.32 SLC30A8 PTPRN2 PTPRN HLA-DQB1 HLA-DQA1 CPE

Biological processes related to Type 1 Diabetes Mellitus 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin secretion involved in cellular response to glucose stimulus GO:0035773 9.62 PTPRN2 PTPRN
2 insulin processing GO:0030070 9.46 SLC30A8 CPE
3 immunoglobulin production involved in immunoglobulin-mediated immune response GO:0002381 9.26 HLA-DQB1 HLA-DQA1
4 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 8.96 HLA-DQB1 HLA-DQA1
5 regulation of secretion GO:0051046 8.92 PTPRN2 PTPRN

Molecular functions related to Type 1 Diabetes Mellitus 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.8 HLA-DQB1 HLA-DQA1

Sources for Type 1 Diabetes Mellitus 5

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....